ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

The vast majority of Roche’s oncology drugs with an orphan drug designation are expected to be blockbusters by 2025, including Perjeta (pertuzumab), Tecentriq (atezolizumab), Herceptin ...

Given its novel mechanism of action and proven efficacy, Herceptin was granted accelerated approval by the FDA in 1998. The dawn of the new millennium marked a paradigm shift in the way breast ...

The mechanism of enzyme catalysis is similar in principle to other types of chemical catalysis, for instance by involving a combination of several different types of catalysis. Determining enzyme ...